Preventing infective complications in inflammatory bowel disease

J. Mill, Ian Lawrance

    Research output: Contribution to journalReview article

    13 Citations (Scopus)


    © 2014 Baishideng Publishing Group Inc. All rights reserved. Over the past decade there has been a dramatic change in the treatment of patients with Crohn's disease and ulcerative colitis, which comprise the inflammatory bowel diseases (IBD). This is due to the increasing use of immunosuppressives and in particular the biological agents, which are being used earlier in the course of disease, and for longer durations, as these therapies result in better clinical outcomes for patients. This, however, has the potential to increase the risk of opportunistic and serious infections in these patients, most of which are preventable. Much like the risk for potential malignancy resulting from the use of these therapies long-term, a balance needs to be struck between medication use to control the disease with minimization of the risk of an opportunistic infection. This outcome is achieved by the physician's tailored use of justified therapies, and the patients' education and actions to minimize infection risk. The purpose of this review is to explore the evidence and guidelines available to all physicians managing patients with IBD using immunomodulating agents and to aid in the prevention of opportunistic infections.
    Original languageEnglish
    Pages (from-to)9691-9698
    JournalWorld Journal of Gastroenterology
    Issue number29
    Publication statusPublished - 2014


    Dive into the research topics of 'Preventing infective complications in inflammatory bowel disease'. Together they form a unique fingerprint.

    Cite this